Analyst Ratings For Laboratory Corp

In the latest quarter, 5 analysts provided ratings for Laboratory Corp LH, showcasing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $242.4, a high estimate of $260.00, and a low estimate of $213.00. Experiencing a 4.19% decline, the current average is now lower than the previous average price target of $253.00.

Interpreting Analyst Ratings: A Closer Look

The standing of Laboratory Corp among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Laboratory Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Laboratory Corp compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Laboratory Corp's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Laboratory Corp's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Laboratory Corp analyst ratings.

Get to Know Laboratory Corp Better

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Key Indicators: Laboratory Corp's Financial Health

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: Laboratory Corp's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 3.54%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -5.51%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Laboratory Corp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.12% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Laboratory Corp's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.99%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Laboratory Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.76, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

What Are Analyst Ratings?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.